AZ rebranded effort: 'Rethink COPD'

Share this article:
AstraZeneca is rolling out an unbranded COPD education campaign featuring comedian and actor Robert Klein.

The campaign, dubbed Rethink COPD, is aimed at getting sufferers to consider their options with respect to diet, exercise and, of course, medication.

“For a lot of these patients, it's really about getting through their day,” said senior brand communications manager Dana Settembrino. “It's a struggle to get out of bed in the morning, it's a struggle to brush their teeth and they want to be independent. It's all about getting them to talk to their doctor and start to think differently about this condition. There's not a lot known about it, and there's a stigma associated with it because most people have gotten it from smoking.”

Klein, a 67-year-old Bronx-born performer whose career has spanned Broadway roles and HBO comedy specials, features on the campaign's website (, where he'll discuss his diagnosis and the steps he's taken to keep his COPD in check.

The site is unbranded, but includes a “Learn about a treatment option” link to a branded Symbicort for COPD site (the drug is indicated for asthma and COPD). The campaign also features 15-second broadcast PSAs aimed at driving traffic to the website.

“This campaign is talking to those patients and saying there's this resource you need to know about,” said Settembrino, “and you can find out what positive lifestyle changes you could be making so you can get through your day.” The tagline of the aspirational campaign is “People with COPD are expecting more.” AstraZeneca worked with agencies Edelman, Cadient and Digitas Health on it.

Klein got his start in the late '60s with Chicago comedy troupe Second City. Recent roles have included appearances on Law and Order: Special Victims Unit and Life on Mars. In 2005, he penned a memoir of his Bronx youth titled The Amorous Busboy of Decatur Avenue.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.